PerpEquities

Equity · Healthcare

Johnson & Johnson (JNJ) perpetual futures

JNJ perpetual futures on 11 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade JNJUSDT.

Johnson & Johnson is a healthcare holding company operating in Innovative Medicine and MedTech segments, developing and selling pharmaceuticals and medical devices.

$266.47+0.6%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · LBank (JNJ/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

11/11 live markets
Venues
11
Live markets
11/11
24h volume
$1.1MCoverage: 10/11 marketsExchange-reported volume: $1.8M
Open interest
$1.1MCoverage: 10/11 markets
Best liquidity
$4.6M
LBank
Tightest spread
+0.8 bps
Bybit
Highest volume
$363.5K
Bybit
Settlement mix
USDT · 11/11
Perp/spot vol.
0.00x
Spot volume $3.2B
OI / float
0.00%
Float $640.7B
Spot performance
1D+1.25%
5D-6.41%
1M+1.07%
6M+15.42%
YTD+30.69%
1Y+31.26%

Venue matrix

11 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BybitTradeJNJ/USDTTrading$266.030.0% APR
0.000% every 8h
+0.8 bps$18.5K$363.5K$490.7KUSDT25x
BingXTradeJNJ-USDTTrading$266.52+5.5% APR
+0.00500% every 8h
+16.9 bps$105.8K$176.1K$2.6KUSDT-
BitgetTradeJNJ/USDTTrading$266.750.0% APR
0.000% every 8h
+8.3 bps$262K$162.8K$238.2KUSDT20x
BinanceTradeJNJ/USDTTrading$266.340.0% APR
0.000% every 8h
+12.4 bps$20.4K$132.5K$54.5KUSDT-
MEXCTradeJNJ/USDTTrading$267.830.0% APR
0.000% every 8h
+44.6 bps$11.5K$101.9K$24.1KUSDT20x
XT.comTradeJNJ/USDTTrading$266.030.0% APR
0.000% every 8h
+5.6 bps$40.4K$61.1K-USDT20x
OKXTradeJNJ/USDTTrading$266.090.0% APR
0.000% every 8h
+4.9 bps$15.1K$43.9K$145.2KUSDT10x
HTXTradeJNJ/USDTTrading$266.72+11.0% APR
+0.010% every 8h
+142.5 bps$87.2K$31.4K$5.5KUSDT-
BitunixTradeJNJ/USDTTrading$266.42-2.6% APR
-0.00236% every 8h
+14.6 bps$50.7K$6.9K$1.1KUSDT20x
Gate.ioTradeJNJ/USDTTrading$266.330.0% APR
0.000% every 8h
+33.1 bps$7.5K$2.6K$178.3KUSDT20x
LBankTradeJNJ/USDTTrading$266.470.0% APR
0.000% every 8h
+14.3 bps$4.6M$683.9K⚠$204.9USDT50x

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Broad liquidity · 8 of 11 venues absorb $10k · Typical cost: +27.7 bps – +60.1 bps

Cheapest execution: LBank · +13.3 bps

Too thin: OKX, Gate.io

No fresh book data: HTX

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

JNJ

Tightest spread

JNJ

Highest volume

JNJ

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-21 · next report 2027-01-26 · Updated 1h ago
All financials →

Valuation & key figures

Market cap
$651B
Updated 1h ago
Revenue
$99.3B
Trailing 12 months
Revenue growth
+7%
FY2026 consensus
Profit margin
16.2%
Net income / revenue, TTM
P/E
40.4×
Forward 24.0× (FY2026)
P/S
6.6×
Price / sales, TTM
Peer P/E
29.3×
Similar listed perps
EV / EBITDA
25.0×
TTM
Free cash flow
$20.6B
Trailing 12 months
Net income
$16.1B
Trailing 12 months
Revenue estimate
$101B
FY2026 consensus
Earnings
2027-01-26
Revenue est. $26.4B · Updated 1h ago
Dividend
$1.34
Per payment · 2026-11-24
Revenue (TTM)$99.3B+7.8% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)25.2%-0.9 pp vs a year agoOperating income $25B
Net income (TTM)$16.1B-35.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$20.6B+5.1% vs a year agoCapex $5.57B
Diluted EPS (TTM)$6.60-36.3% vs a year agoSum of the last 4 quarters
Net cash-$27.4B-0.7% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-13): revenue in line, EPS beat by 2.8%Revenue $25.4B vs $25.4B expected (+0.1%); EPS $2.59 vs $2.52 (+2.8%).
  • Revenue growth slowing: 5.9% year on yearQ3 '26 revenue $25.4B, against an average of 8.1% over the four quarters before.
  • Operating margin 25.2% (TTM), -0.9 pp on a year agoOperating income grew 4.0% while revenue grew 7.8%.
  • 41.0% of pre-tax profit is eaten by non-operating lossesPre-tax income $17.7B vs operating income $25B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Segments in Q3 '26

from the filing
SegmentRevenuey/yOp. incomeMargin
Innovative Medicine$16.8B+7.7%––
Med Tech$8.64B+2.5%––
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 313 lines Johnson & Johnson reported to the SEC

Next catalyst

Catalysts

Earnings
2027-01-26
Revenue est. $26.4B · Updated 1h ago
Dividend
$1.34
2026-11-24

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202611.11$101.2B+7%12
FY 202711.57$107.6B+6%12
FY 202813.92$116.5B+8%6
FY 202915.56$125.3B+8%2
FY 203017.44$135.2B+8%4
Q1 20272.68$25.5B+6%5
Source: FMP · Consensus

Company events

6
2027-01-26EarningsActual - / Estimate 2.91-
2026-11-24Dividend$1.34-
2026-10-13Earnings · Before market openActual 2.59 / Estimate 2.52Beat
2026-08-25Dividend$1.34-
2026-07-15EarningsActual 2.90 / Estimate 2.85Beat
2026-05-26Dividend$1.34-

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 11:57 AM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Joaquin Duato
Employees
141,700
IPO date
Jan 2, 1962
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei5.41
Piotroski scorei6/9
Overall ratingiB+
Owner earningsi$6.68B$2.73 per share
ESG risk ratingiB+Industry rank: 3/28

Rating factors

Return on equityi
5/5
Return on assetsi
5/5
Debt to equityi
2/5
Price to earningsi
1/5
Price to booki
1/5
Market cap history
$661.99B+0.1%Aug 2026 – Nov 2026
$619.06B$655.31B$691.56BHigh: $691.56B · 2026-11-16Low: $619.06B · 2026-10-05Latest: $661.99B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $661.99B · 2026-11-20High: $691.56B · 2026-11-16Low: $619.06B · 2026-10-05
Largest fund holders
FundWeightShares held
VOO1.01%64M
VTI0.9%60.4M
IVV1.06%32.4M
1657.T0.81%32.4M
XAW.TO0.63%32.4M
XUU.TO0.95%32.4M
SPY1.06%29.8M
FXAIX0.97%29.4M
VTV2.37%23.2M
XLV10%17.8M
VECA.S0.27%14.3M
VIG2.74%13.7M

Analyst track record

How the analysts covering JNJ have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings173489
Analysts2736
Buy / hold / sell125 / 47 / 1284 / 204 / 1
Upgrades / downgrades / initiations2 / 2 / 18 / 5 / 5
Price targets hit / missed77 / 86 (47%)365 / 86 (81%)
Avg. return after a rating (TipRanks)+2.5%+33.2%
Best / worst call+142.9% / -16.5%+142.9% / -16.5%

After buy calls on this stock: median 21-day move +1.3% vs S&P 500 -1.1% (n = 305)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Asad HaiderGoldman Sachs100% hit rate on this stock · 9 targets measuredBuytarget $280Oct 26, 2026
  2. Joanne WuenschCiti64% hit rate on this stock · 14 targets measuredBuytarget $303Oct 5, 2026
  3. Josh JenningsTD Cowen57% hit rate on this stock · 21 targets measuredBuytarget $250Apr 23, 2026

Latest ratings

DateAnalystCallTarget
Nov 20, 2026Chris SchottJ.P. MorganNov 20, 2026HoldReiterated$300↗
Nov 17, 2026Jason GerberryBank of America SecuritiesNov 17, 2026HoldMaintained$292↗
Nov 17, 2026David RisingerLeerink PartnersNov 17, 2026BuyMaintained$272↗
Nov 11, 2026Jason GerberryBank of America SecuritiesNov 11, 2026HoldReiterated$275↗
Nov 9, 2026Louise ChenScotiabankNov 9, 2026BuyMaintained$305↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$220$240$260$280Dec 25 · Buy 14 · Hold 8 · Sell 0Dec 25Jan 26 · Buy 14 · Hold 7 · Sell 0Feb 26 · Buy 14 · Hold 8 · Sell 0Feb 26Mar 26 · Buy 14 · Hold 8 · Sell 0Apr 26 · Buy 12 · Hold 6 · Sell 0Apr 26May 26 · Buy 13 · Hold 6 · Sell 0Jun 26 · Buy 13 · Hold 6 · Sell 0Jun 26Jul 26 · Buy 18 · Hold 6 · Sell 0Aug 26 · Buy 18 · Hold 5 · Sell 0Aug 26Sep 26 · Buy 18 · Hold 6 · Sell 0Oct 26 · Buy 17 · Hold 7 · Sell 1Oct 26Nov 26 · Buy 17 · Hold 6 · Sell 1Dec 25 · avg. target $217Jan 26 · avg. target $229Feb 26 · avg. target $231Mar 26 · avg. target $242Apr 26 · avg. target $264May 26 · avg. target $264Jun 26 · avg. target $264Jul 26 · avg. target $278Aug 26 · avg. target $281Sep 26 · avg. target $286Oct 26 · avg. target $279Nov 26 · avg. target $282Dec 25 · month-end close $207Jan 26 · month-end close $227Feb 26 · month-end close $248Mar 26 · month-end close $244Apr 26 · month-end close $230May 26 · month-end close $225Jun 26 · month-end close $254Jul 26 · month-end close $256Aug 26 · month-end close $266Sep 26 · month-end close $265Oct 26 · month-end close $273Nov 26 · month-end close $270

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 173 ratings

Frequently asked questions

Where can I trade JNJ perpetual futures?

Johnson & Johnson (JNJ) perpetual futures trade on 11 crypto venues, including LBank, Bybit, BingX. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade JNJ around the clock?

Yes. Unlike the underlying stock, JNJ perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on JNJ perpetuals?

Right now the JNJ perp funding rate is 0.0% annualized (venue median), ranging from -2.6% to +11.0% across 11 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the JNJ perp price compare to the Johnson & Johnson stock?

The venue-median JNJ perp mark is $266.4 versus a reference stock price of $266.5, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a JNJ perpetual future?

A JNJ perpetual is a derivative that tracks the price of Johnson & Johnson with no expiry date. It lets you take long or short exposure to Johnson & Johnson on crypto venues, around the clock.

What is JNJUSDT perpetual?

JNJUSDT is the symbol most crypto exchanges use for the Johnson & Johnson perpetual settled in USDT (Tether). It tracks the JNJ share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

JNJ perpetuals · perpequities.comJNJ perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/jnj-perp"><img src="https://perpequities.com/badge/jnj-perp.svg" width="240" height="64" alt="JNJ perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of JNJ perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for JNJ — one email every Sunday.

Watchlist and alerts

Price and funding alerts for JNJ, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X